Looking Better: Digital therapy reduces liver fat in 90 days

Better Therapeutics Inc.’s prescription digital therapeutic (PDT) received U.S. FDA breakthrough device designation for metabolic dysfunction-associated steatohepatitis (MASH), an advanced form of fatty liver disease that increases the risk of cirrhosis, liver failure and liver cancer but has few good treatments available.

Related Keywords

,Better Therapeutics Inc ,Better Therapeutics ,Bioworld Medtech ,Hepatology ,Prescription Digital Therapeutic ,Dpdt ,Metabolic Dysfunction Associated Liver Disease ,Metabolic Dysfunction Associated Steatotic Liver Disease ,Masld ,Non Alcoholic Fatty Liver Disease ,Nafld ,Non Alcoholic Steatohepatitis ,Nash ,Metabolic Dysfunction Associated Steatohepatitis ,Smash ,Fibrosis ,Breakthrough Device Designation ,Us ,Fda ,Regulatory ,